Marseille

• Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r … Recruiting
  2024-516196-32-00 5 2017-01-01 breast cancer
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 9 2016-11-17 Metastatic Castration-Resistant Prostate Cancer
• Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma … Recruiting
  2024-512827-36-00 4 2016-10-17 Penis carcinoma
• Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index Recruiting
  2024-515432-71-00 5 2016-09-13 gastrointestinal stromal tumor
• AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting
  2024-514791-40-00 9 2016-08-03 pediatric cancer
• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of … Recruiting
  2023-510566-27-00 4 2014-02-27 Advanced / Metastatic cancers
• MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting
  2024-515626-92-00 4 2013-10-18 recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
• GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. Recruiting
  2024-516358-23-00 5 2013-06-24 Gastric adenocarcinoma
• Conservative treatment of patients with retinoblastoma Recruiting
  2024-517275-21-00 4 2012-02-20 Retinoblastoma
• Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting
  2024-517390-24-00 5 2011-04-26 Ovarian epithelial cancer : intraperitoneal resectable relapse
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended recruitment
  2025-521302-17-00 10 2026-05-26 Hihg risk of cholangiocarcinoma intra hépatic resectable
• A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under cod … Ended recruitment
  2022-502942-29-01 9 2026-03-23 Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
• Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended recruitment
  2024-516873-57-00 10 2026-01-13 Acute myeloid leukemia in adults aged 18 to 60
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part … Ended recruitment
  2023-506146-23-00 4 2025-11-17 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
• A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP Ended recruitment
  2025-521249-25-00 7 2025-10-30 MTAP-deleted advanced or metastatic solid tumors
• A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta … Ended recruitment
  2024-520155-24-00 4 2025-10-16 Metastatic castration resistant prostate cancer (mCRPC)
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S

Showing 793–816 of 1,485 trials